Profile data is unavailable for this security.
About the company
Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Company’s customers are pharmaceutical companies worldwide.
- Revenue in NOK (TTM)454.84m
- Net income in NOK78.06m
- Incorporated2015
- Employees77.00
- LocationVistin Pharma ASAOstensjoveien 27OSLO 0661NorwayNOR
- Phone+47 35984200
- Websitehttps://www.vistin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corline Biomedical AB | 8.10m | -25.55m | 444.58m | 13.00 | -- | 5.14 | -- | 54.89 | -1.02 | -1.02 | 0.3142 | 3.15 | 0.0862 | -- | 10.59 | 581,461.60 | -27.20 | -8.36 | -29.49 | -9.10 | 82.54 | 121.50 | -315.49 | -53.37 | -- | -1,153.67 | 0.00 | -- | -60.95 | 55.82 | -1,182.15 | -- | 9.13 | -- |
| Enzymatica AB (publ) | 56.50m | -58.01m | 481.14m | 21.00 | -- | 3.31 | -- | 8.52 | -0.2257 | -0.2257 | 0.2198 | 0.559 | 0.292 | 1.26 | 4.54 | 2,510,953.00 | -29.98 | -29.10 | -31.26 | -34.48 | 63.76 | 63.82 | -102.68 | -73.32 | -- | -- | 0.0095 | -- | -10.47 | -5.76 | -6.94 | -- | -14.62 | -- |
| Moberg Pharma AB (publ) | 13.39m | -276.20m | 494.78m | 6.00 | -- | 0.6582 | -- | 36.95 | -5.52 | -5.52 | 0.2672 | 14.40 | 0.0153 | 0.9991 | 1.87 | 1,388,556.00 | -31.46 | -- | -32.04 | -- | 52.35 | -- | -2,062.80 | -- | 15.81 | -- | 0.0044 | -- | -- | -- | -1,109.46 | -- | -- | -- |
| Navamedic ASA | 539.42m | -39.43m | 537.18m | 45.00 | -- | 2.56 | -- | 0.9959 | -2.21 | -2.21 | 27.98 | 8.74 | 0.883 | 3.27 | 6.40 | 12,843,290.00 | -6.45 | -0.3087 | -8.75 | -0.4895 | 37.32 | 39.37 | -7.31 | -0.2916 | 0.7697 | 0.192 | 0.5978 | -- | 3.80 | 23.00 | 59.92 | -- | 35.76 | -- |
| Dicot Pharma AB | 135.00k | -90.00m | 666.31m | 4.00 | -- | 6.89 | -- | 4,935.65 | -0.0459 | -0.0459 | 0.00007 | 0.0449 | 0.001 | 10.68 | 0.0371 | 42,000.00 | -69.50 | -94.78 | -75.43 | -111.46 | -61,341.27 | -32,616.05 | -66,663.49 | -37,576.05 | 8.82 | -- | 0.00 | -- | -88.60 | -47.16 | -30.66 | -- | -- | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -85.42m | 814.57m | 10.00 | -- | 6.33 | -- | -- | -5.92 | -5.92 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.19 | -22.82 | -48.56 | -24.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.24 | -- | -- | -- |
| Cinclus Pharma Holding publ AB | 51.88m | -189.69m | 858.63m | 19.00 | -- | 1.90 | -- | 16.55 | -3.80 | -3.80 | 1.04 | 9.07 | 0.0777 | -- | 15.47 | 3,724,539.00 | -28.43 | -- | -32.01 | -- | -- | -- | -365.65 | -- | -- | -- | 0.0197 | -- | -23.14 | -- | 21.89 | -- | -- | -- |
| Vistin Pharma ASA | 454.84m | 78.06m | 886.89m | 77.00 | 11.36 | 2.84 | 8.90 | 1.95 | 1.76 | 1.76 | 10.26 | 7.05 | 1.12 | 1.87 | 6.20 | -- | 19.20 | 1.65 | 23.64 | 1.99 | 66.40 | 62.28 | 17.16 | 1.88 | 1.16 | -- | 0.063 | -- | -1.45 | 13.56 | 37.62 | -1.03 | 17.32 | -- |
| Arcticzymes Technologies ASA | 103.07m | 7.66m | 1.10bn | 55.00 | 147.50 | 3.34 | 66.84 | 10.70 | 0.1464 | 0.1464 | 1.97 | 6.47 | 0.2967 | 0.295 | 1.91 | 1,874,073.00 | 2.20 | 13.28 | 2.32 | 14.39 | 95.42 | 96.20 | 7.43 | 31.41 | 15.45 | -- | 0.0184 | 0.00 | -12.26 | 18.22 | -56.40 | -- | 53.98 | -- |
| Orexo AB | 414.00m | -215.47m | 1.11bn | 72.00 | -- | 2.10 | -- | 2.68 | -5.80 | 18.42 | 11.15 | 14.22 | 0.4073 | 1.29 | 2.02 | 5,366,667.00 | -21.20 | -28.03 | -29.75 | -42.57 | 89.96 | 83.88 | -52.04 | -74.89 | 3.70 | -3.00 | 0.5005 | -- | -12.46 | -47.69 | 15.63 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -113.87m | 1.18bn | 8.00 | -- | 5.64 | -- | -- | -2.20 | -2.20 | 0.00 | 3.65 | 0.00 | -- | -- | 0.00 | -45.16 | -85.38 | -50.22 | -99.19 | -- | -- | -- | -- | -- | -63.96 | 0.0071 | -- | -- | -- | 61.82 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Vistin Pharma ASA's reporting currency: Norwegian Krone NOK
14.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Holmen Fondsforvaltning ASas of 15 Dec 2025 | 4.37m | 9.86% |
| MP Pensjon PKas of 15 Dec 2025 | 1.72m | 3.88% |
| Melesio Capital ASas of 15 Dec 2025 | 397.11k | 0.90% |
| Mandarine Gestion SAas of 30 Jun 2025 | 151.51k | 0.34% |
More ▼
Data from 30 Sep 2025 - 27 Jan 2026Source: FactSet Research Systems Inc.
